FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

	OMB Number: 3235-0287						
	Estimated average burden						
l	hours per response:	0.5					

Instruction 1(b)).		Filed pursuant to Section 16(a) of the Securities Exchange Act of 193	34			
			or Section 30(h) of the Investment Company Act of 1940				
1. Name and Addr Valamehr Ba		g Person [*]	2. Issuer Name and Ticker or Trading Symbol <u>FATE THERAPEUTICS INC</u> [FATE]		ionship of Re all applicable Director Officer (give)	son(s) to Issuer 10% Owner Other (specify
(Last) C/O FATE TH	(First) ERAPEUTIC	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 01/10/2023		below) Chief R&D Of		below) fficer
12278 SCRIPPS SUMMIT DRIVE (Street) SAN DIEGO CA 92131							
			4. If Amendment, Date of Original Filed (Month/Day/Year)	Line)	ividual or Joint/Group Filing (Check Appli Form filed by One Reporting Person		
·	CA (Stata)				Form filed by Person	y More thar	n One Reporting
(City)	(State)	(Zip)			<u> </u>		
		Table I - Non-l	Derivative Securities Acquired, Disposed of, or Ben	eticially (Owned		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)						5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(
Common Stock	01/10/2023		S ⁽¹⁾		10,917	D	\$5.24 ⁽²⁾	168,917	D	

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2022, the shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2022, the shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2 not represent discretionary trades by the Reporting Person.

2. Represents the weighted average sale price of the shares sold ranging from \$5.12 to \$5.36 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote

Remarks:

<u>/s/ Cindy Tahl, as Attorney-in-</u>	01/11/2023
Fact	01/11/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See